Black Rock Inc. Mirati Therapeutics, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$41.99 - $62.38 $13.5 Million - $20.1 Million	321,891 Added 9.08%	3,866,202 $227 Million
Q3 2023 Nov 13, 2023	BUY	$27.8 - $45.35 $6.29 Million - $10.3 Million	226,292 Added 6.82%	3,544,311 $154 Million
Q2 2023 Aug 11, 2023	BUY	$36.13 - $49.49 $2.93 Million - $4.02 Million	81,140 Added 2.51%	3,318,019 $120 Million
Q1 2023 May 12, 2023	BUY	$36.54 - $54.26 $21 Million - $31.1 Million	573,957 Added 21.55%	3,236,879 $120 Million
Q4 2022 Feb 13, 2023	BUY	$41.27 - $98.62 $9.71 Million - $23.2 Million	235,171 Added 9.69%	2,662,922 $121 Million

Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $1.03 Million - $1.51 Million	17,385 Added 0.72%	2,427,751 $170 Million
Q2 2022 Aug 12, 2022	SELL	$39.16 - $88.71 $15.2 Million - $34.4 Million	-387,272 Reduced 13.84%	2,410,366 $162 Million
Q1 2022 May 12, 2022	BUY	$75.82 - $150.97 $3.11 Million - $6.18 Million	40,963 Added 1.49%	2,797,638 $230 Million
Q4 2021 Feb 10, 2022	BUY	$132.01 - $190.29 $13 Million - $18.7 Million	98,465 Added 3.7%	2,756,675 $404 Million
Q3 2021 Nov 09, 2021	SELL	$132.13 - $177.45 $48.8 Million - $65.5 Million	-369,295 Reduced 12.2%	2,658,210 $470 Million
Q2 2021 Aug 11, 2021	BUY	$144.0 - $179.73 $436 Million - $544 Million	3,027,505 New	3,027,505 $489 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.